Neoadjuvant Treatment for RCC Downstaging
For locally advanced, non-metastatic renal cell carcinoma requiring downstaging, combination immune checkpoint inhibitor plus VEGFR-TKI therapy (such as pembrolizumab plus lenvatinib, pembrolizumab plus axitinib, or nivolumab plus cabozantinib) is the recommended neoadjuvant approach, with treatment duration of approximately 3-7 months prior to surgery.
Current Guideline Position
The ESMO 2024 guidelines 1 do not explicitly endorse routine neoadjuvant therapy for localized RCC, as the standard approach remains upfront surgery for resectable disease. However, the guidelines strongly support these same combination regimens (ICI plus VEGFR-TKI) as first-line therapy for advanced/metastatic disease, establishing their efficacy and safety profile in RCC 1.
Evidence for Neoadjuvant Approach
Combination ICI-TKI Regimens (Preferred)
Recent evidence demonstrates that combination ICI-TKI therapy achieves superior tumor downstaging compared to monotherapy 2, 3:
- Radiographic tumor reduction: Median 27% reduction in tumor diameter 3
- Objective response rates: Approximately 26% partial response rate across studies 4
- Pathologic complete response: 17-27% of patients achieve complete pathologic response 3, 5
- Venous thrombus reduction: 50% of patients with tumor thrombus show Mayo level reduction 3
- T-stage downstaging: Achieved in 53% of patients 3
The most commonly used regimen in contemporary studies is pembrolizumab plus a VEGFR-TKI (lenvatinib, axitinib, or cabozantinib), with 88% of patients receiving this combination in recent series 3.
Treatment Duration
Median treatment duration of 7 months appears optimal based on recent data 3, though some patients respond adequately with 3-4 months of therapy 2, 5. Treatment should continue until maximal response or planned surgical date.
Surgical Feasibility and Safety
Critical findings regarding perioperative outcomes:
- Surgery remains feasible in 100% of appropriately selected patients after neoadjuvant therapy 3
- No consistent increase in surgical morbidity: Clavien-Dindo grade ≥III complications occur in approximately 18% of cases, primarily in complex thrombus resections 3
- Perioperative outcomes comparable to upfront surgery in terms of blood loss and complications 6
- Nephron-sparing surgery becomes feasible: 90% of patients with imperative indications achieve measurable tumor decrease enabling partial nephrectomy 5
Clinical Scenarios for Neoadjuvant Therapy
Primary Indications:
- Locally advanced disease with venous tumor thrombus requiring complex surgical resection
- High-complexity tumors (RENAL score ≥10) where downstaging could enable partial nephrectomy
- Imperative partial nephrectomy candidates (solitary kidney, bilateral tumors, chronic kidney disease) with otherwise unresectable masses 5
- Borderline resectable disease where tumor reduction improves surgical feasibility
Contraindications:
- Standard resectable localized RCC (surgery remains first-line)
- Patients requiring urgent nephrectomy for bleeding or other complications
- Poor performance status precluding systemic therapy
Important Caveats
Radiographic-pathologic discordance is common: Radiographic response does not reliably predict pathologic response 3. This means imaging may underestimate or overestimate actual tumor viability, requiring careful surgical planning regardless of imaging response.
Renal function decline: Expect some decline in renal function with neoadjuvant therapy, though nephron-sparing approaches still preserve function better than radical nephrectomy 6.
Limited long-term survival data: While early disease-free survival appears favorable 2, 3, mature overall survival data from prospective trials are lacking. Median DFS of 28 months has been reported 3.
Monitoring During Neoadjuvant Therapy
- Interval imaging every 2-3 months to assess response
- Monitor for disease progression: Surgery should not be delayed if progression occurs
- Toxicity management: Dose reductions are common (approximately 69% with lenvatinib-pembrolizumab) 7
- Surgical planning should occur at maximal response or by 6-7 months if stable disease
Alternative Approaches
VEGFR-TKI monotherapy (sunitinib, pazopanib) demonstrates only mild-to-moderate tumor shrinkage and is inferior to combination therapy 2. ICI monotherapy shows limited efficacy in early-phase neoadjuvant studies 2. These should not be used when combination therapy is feasible.